Five-year risk of incident pancreatic cancer in patients with type 2 diabetes, with and without obesity (Comparison between propensity-score matched groups)

Size/group	Exposure group	Comparison group	# of cases (overall risk) (Exposure group)	# of cases (overall risk) (Comparison group)		HR (95% CI)
	Obesity					
26,727	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	49 (0.18%)	121 (0.45%)		0.36 (0.26–0.51)
17,057	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	52 (0.31%)	67 (0.39%)	├──	0.73 (0.51–1.05)
42,168	GLP-1RA(+)DDP-4i(-)	DPP-4i(+)GLP-1RA(-)	134 (0.32%)	154 (0.37%)	├─ ■──	0.78 (0.62-0.99)
19,760	GLP-1RA(+)SGLTi2(-)	SGLT2i(+)GLP-1RA(-)	64 (0.32%)	77 (0.39%)	├───	0.75 (0.54–1.05)
41,552	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	104 (0.25%)	163 (0.39%)	⊢	0.58 (0.45–0.74)
18,087	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	58 (0.32%)	82 (0.45%)	⊢	0.64 (0.46-0.89)
	No obesity					
25,038	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	51 (0.20%)	163 (0.65%)		0.28 (0.21–0.39)
17,095	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	60 (0.35%)	62 (0.36%)		0.93 (0.65–1.33)
50,112	GLP-1RA(+)DDP-4i(-)	DPP-4i(+)GLP-1RA(-)	167 (0.33%)	186 (0.37%)	├	0.83 (0.67–1.02)
31,118	GLP-1RA(+)SGLTi2(-)	SGLT2i(+)GLP-1RA(-)	120 (0.39%)	173 (0.56%)	⊢ ■	0.64 (0.51-0.81)
39,597	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	139 (0.35%)	162 (0.41%)	⊢ ■	0.80 (0.64–1.01)
35,459	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	139 (0.39%)	165 (0.47%)		0.80 (0.64–1.00)
					0.30 0.400.50 0.70 0.90 2 Hazard Ratio (HR)	2.0 3.00